Form 4: Acasti Pharma Inc. Executive R. Loch Macdonald Reports Stock Option Grant
SEC Form 4 Filing
R. Loch Macdonald, Chief Medical Officer of Acasti Pharma Inc., reports the acquisition of stock options.
Summary
- On May 6, 2024, R. Loch Macdonald, Chief Medical Officer of Acasti Pharma Inc., was granted 25,380 stock options under the company's stock option plan.
- The options have an exercise price of $2.96.
- The options vest quarterly in equal installments over a 36-month period and expire on May 6, 2034.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that the company is using stock options as part of its compensation strategy.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the long-term success of the company.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of stock options grant |
| 05/06/2034 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.